Salute e Benessere
New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms
The research team at Kent enrolled 164 active athletes who were randomized to use either ColdZyme or a placebo spray in their throat at the first signs of upper respiratory infection symptoms. Participants also submitted throat swabs for researchers to analyze the presence of viruses during symptom periods. The final results are based on 154 participants, as 10 of the 164 enrolled athletes were lost in follow-up. The results showed that athletes using the active product had significantly lower symptom score ratings and fewer lost training days due to colds compared to the placebo group (see figure below). Additionally, the findings demonstrated a significant reduction in viral load (94%) for rhinovirus—the most common cause of colds—when treated with ColdZyme, along with lower symptom scores.
- This shows that ColdZyme addresses the underlying cause of upper respiratory infections by inhibiting viruses' ability to infect cells and limiting their spread. This results in less tissue damage in the airways and milder symptoms. The findings are very promising, and the reduced illness duration can be of practical benefit to both athletes and the general population, says Glen Davison , professor of Sport and Exercise Sciences in the School of Natural Sciences at the University of Kent, UK .
The study, conducted by the research team in Vienna , illustrated that ColdZyme effectively blocked cold viruses from adhering to the cell types present in the upper respiratory tract. Using human epithelial cells in models simulating different parts of the upper respiratory tract, such as the nose and throat, these models were infected with rhinovirus—the most common cause of colds. The researchers compared the effects of spraying the epithelial cells with either ColdZyme or a control (standard saline solution). When the cells were treated with ColdZyme, a significant reduction in viral load was observed.
- These results are remarkable because ColdZyme not only significantly reduced the viral load for SARS-CoV-2 variants and Influenza A and B as previously demonstrated, but also for rhinoviruses in our upper respiratory tract model. After treatment with ColdZyme, previously infected tissue cultures appeared almost uninfected, with intact cell nuclei, undamaged cilia, and only a few remaining virus particles compared to infected cultures mock-treated with saline solution before infection says Doris Wilflingseder, professor of infectious diseases at the Ignaz Semmelweis Institute and the Vetmeduni Vienna.
- Most people see colds as something you just have to endure. Therefore, we are very positive about the results from two independent, researcher-initiated studies, which in different ways show that ColdZyme addresses the root cause – the virus – rather than just alleviating the symptoms. The product shortens the duration of the illness and relieves discomfort, which we believe is valuable for everyone," says Claus Egstrand, CEO of Enzymatica.
https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136
In connection with the publication of the results from two research studies on ColdZyme, Enzymatica AB invites you to a digital press briefing on
5 March 2025 . During the press conference, the researchers behind the studies will present their findings and be available for questions. A separate invitation with further details will be sent out shortly.
ColdZyme® is an oral spray that should be used at the first signs of cold and flu-like symptoms. When sprayed into the back of the throat, it immediately creates a barrier that captures the viruses causing the symptoms and inhibits their ability to infect other cells and replicate.
ColdZyme is a medical device certified under the EU MDR regulation (Class III) by the Notified Body Eurofins. This certification entails stricter requirements for clinical evidence, safe design, and market surveillance.
The information in this press release is such that Enzymatica is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on 28 February, 2025 , at 16.00 CET.
Claus Egstrand, CEO, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/enzymatica-ab/r/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections--reduc,c4110199
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms-302388714.html